A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering
Leusink, Maarten; Leusink, Maarten; Maitland-Van Der Zee, Anke H.; Ding, Bo; Drenos, Fotios; Drenos, Fotios; Van Iperen, Erik P A; Van Iperen, Erik P A; Warren, Helen R.; Warren, Helen R.; Caulfield, Mark J.; Caulfield, Mark J.; Cupples, L. Adrienne; Cupples, L. Adrienne; Cushman, Mary; Hingorani, Aroon D.; Hoogeveen, Ron C.; Hovingh, G. Kees; Kumari, Meena; Lange, Leslie A.; Munroe, Patricia B.; Munroe, Patricia B.; Nyberg, Fredrik; Nyberg, Fredrik; Schreiner, Pamela J.; Sivapalaratnam, Suthesh; De Bakker, Paul I W; De Bakker, Paul I W; De Boer, Anthonius; Keating, Brendan J.; Asselbergs, Folkert W.; Asselbergs, Folkert W.; Asselbergs, Folkert W.; Onland-Moret, N. Charlotte
(2016) Pharmacogenomics, volume 17, issue 6, pp. 583 - 591
(Article)
Abstract
Aim: To find new genetic loci associated with statin response, and to investigate the association of a genetic risk score (GRS) with this outcome. Patients & methods: In a discovery meta-analysis (five studies, 1991 individuals), we investigated the effects of approximately 50000 single nucleotide polymorphisms on statin response, following up
... read more
associations with p < 1 × 10-4 (three independent studies, 5314 individuals). We further assessed the effect of a GRS based on SNPs in ABCG2, LPA and APOE. Results: No new SNPs were found associated with statin response. The GRS was associated with reduced statin response: 0.0394 mmol/l per allele (95% CI: 0.0171–0.0617, p = 5.37 × 10-4). Conclusion: The GRS was associated with statin response, but the small effect size (˜2% of the average low-density lipoprotein cholesterol reduction) limits applicability.
show less
Download/Full Text
Keywords: pharmacogenetics cholesterol, risk score, statin therapy, Taverne
ISSN: 1462-2416
Publisher: Future Medicine Ltd.
(Peer reviewed)
